TADLIQ
- Product NDC
- 46287-045
- 11-digit product format
- 462870045
- Labeler code
- 46287
- Product ID
- 46287-045_cf6ec62b-5d5e-49ed-8d46-8a759d0e2b93
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Tadalafil
- Dosage form
- SUSPENSION
- Route
- ORAL
- Labeler
- CMP Pharma, Inc.
- Application
- NDA214522
- Marketing category
- NDA
- Marketing start
- 2022-08-30
- Substance
- TADALAFIL
- Active strength
- 20 mg/5mL
- Pharmacologic classes
- Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- TADLIQ
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| TADALAFIL | 20 mg/5mL |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | 742SXX0ICT |
| Rxcui | 2613563, 2613569 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 46287-045-15 | TADLIQ | 150 mL in 1 BOTTLE | SUSPENSION | 150 | | 6 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 46287-045 | TADLIQ (TADALAFIL) SUSPENSION [CMP PHARMA, INC.] | 5 | Current NDC, Legacy NDC, 1 package rows | 20231023_7a909b25-3772-403e-a5fe-e4a040293fb7.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 46287-045-15 | 46287004515 | 150 mL in 1 BOTTLE (46287-045-15) | 150 ml | 2022-08-30 | 0000-00-00 | No | No | Current |